COMPANY
KARE Biosciences
KARE Biosciences is developing KAR101 (ramatroban) as a disease modifying therapy for various indications including COVID-19. From company website Source · Oct 13, 2026
Timeline
- Trial start 2: Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05706454 | Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia | 2 | Unknown status (ClinicalTrials.gov) | Nov 10, 2022 | Jul 1, 2024 (estimated) |